Oncology

Latest News

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

By AJMC Contributor

July 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

August 11th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 11th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

November 30th 2015

Pharmaceutical Advertising Increased Prescription Drug Utilization, Study Reports

Surabhi Dangi-Garimella, PhD

Relaxed direct-to-consumer advertising restrictions for drugs by the FDA in 1997 has precipitated an increase in prescription drug utilization, not just among Medicare enrollees, but also among non-elderly users.

Dr Kavita Patel Outlines How Oncology Is Ripe for Delivery Reform

November 27th 2015

Dr Kavita Patel Outlines How Oncology Is Ripe for Delivery Reform

Oncology, like primary care, is ripe for delivery reform, but it has remained stuck in a fee-for-service mindset, said Kavita Patel, MD, fellow in economic studies and managing director at Brookings Institution.

November 27th 2015

American College of Physicians Recommends More Use of Generic Medications

Surabhi Dangi-Garimella, PhD

The American College of Physicians has published a paper in the Annals of Internal Medicine that advices clinicians to prescribe generic drugs whenever possible.

November 25th 2015

At Thanksgiving, Take Time to Collect Family Medical History

Mary K. Caffrey

Waiting until there's a cancer diagnosis or other crisis is not the time to be taking the family's medical history. Testing companies and genetic counselors encourage families to share information when they are all in one place.

Joy Larsen Haidle Discusses How Patients Should Use Genetic Tests

November 24th 2015

Joy Larsen Haidle Discusses How Patients Should Use Genetic Tests

Patients considering using a genetic test should meet with a genetic counselor first to get a better understanding of the patient's goal for getting the test done and determine the likelihood that a test might be useful, explained Joy Larsen Haidle, MS, CGC, president of the National Society of Genetic Counselors.

November 24th 2015

Another First for Nivolumab: Approved as Frontline for BRaf Wild Type Melanoma

Surabhi Dangi-Garimella, PhD

The approval follows 5 months after Bristol-Myers Squibb submitted phase 3 results of the Checkmate-066 trial for FDA review.

November 23rd 2015

Nivolumab Approved for Third Indication: Advanced Renal Cell Carcinoma

Surabhi Dangi-Garimella, PhD

Two months after being granted a Breakthrough Therapy designation by the FDA for metastatic renal cell carcinoma (mRCC), nivolumab was today approved by regulators for treating mRCC patients who have failed a certain type of prior therapy.

November 23rd 2015

Decade-Long Screening Efforts Bear Fruit for CRC Screening in New York City

Surabhi Dangi-Garimella, PhD

A state-led program, initiated in 2003, has nearly doubled screening colonoscopy rates in New York City and also eliminated racial and ethnic disparities in the process.

November 22nd 2015

Staying Focused on the Cancer Patient, Amid Rising Drug Costs and New Payment Models

Giving cancer patients what they want and need is the goal, but getting there isn't easy, according to healthcare experts who took part in Patient-Centered Oncology Care 2015, presented November 19-20, 2015, by The American Journal of Managed Care. Drug costs demand difficult conversations about value, and changes in the law require oncologists to learn whole new ways to be paid.

November 21st 2015

As Prospect of Risk for Doctors Looms, Cost Conversation Shifts in Cancer Care

Mary K. Caffrey

Three years after Memorial Sloan Kettering Cancer Center refused to add Zaltrap to its formulary due to cost, value is part of the national conversation in cancer care. The new question is what will happen when physicians assume risk.

Dr Scott Gottlieb Worries About More FDA Regulation in Diagnostic Testing

November 21st 2015

Dr Scott Gottlieb Worries About More FDA Regulation in Diagnostic Testing

If the FDA steps in to regulate laboratory-developed tests, it will slow down innovation, add costs to the development of the product, and likely decrease the number of tests that come out, but the public health benefits of increased oversight might be worth it, said Scott Gottlieb, MD, resident fellow at the American Enterprise Institute.

Dr Peter Bach Examines the Problems of the 340B Drug Pricing Program

November 21st 2015

Dr Peter Bach Examines the Problems of the 340B Drug Pricing Program

While the 340B Drug Pricing Program was designed to help facilities that take care of impoverished patients with low-cost drugs, what the program has morphed into is almost the opposite of what it was intended to do, said Peter Bach, MD, MPP, director of Memorial Sloan Kettering's Center for Health Policy and Outcomes.

November 21st 2015

Are PBMs the Answer to Managing the High Cost in Oncology Care?

Surabhi Dangi-Garimella, PhD

A pharmacist who engages in formulary decisions, a medical director for population management for a private health exchange, and an innovations leader at a pharmacy benefit manager, took to the podium at the Patient-Centered Oncology Care meeting on November 20, 2015, to discuss cost-saving strategies in oncology and whether benefit managers can play a role in reining-in some of these costs.

November 20th 2015

End-of-Life and Palliative Care to Be Discussed During AJMC's November 24 Tweetchat

During a tweetchat on November 24 at 3:30 pm EST, Amy Berman, RN, BS, and Judith R. Peres, LCSW-C, will discuss patient-centered care, palliative care, and end-of-life care.

Dr Bruce Quinn Describes How Europe and the US Regulate Diagnostic Tests Differently

November 20th 2015

Dr Bruce Quinn Describes How Europe and the US Regulate Diagnostic Tests Differently

While the FDA could regulate diagnostic tests the way they are in Europe-through simple verification that the test is accurate-the FDA has not chosen to do that and comes closer to requiring clinical utility, explained Bruce Quinn, MD, PhD, senior director at FaegreBD Consulting.

Dr Julie Vose Weighs in on Value Calculators, MACRA

November 20th 2015

Dr Julie Vose Weighs in on Value Calculators, MACRA

Julie M. Vose, MD, MBA, FASCO, president of the American Society of Clinical Oncology (ASCO), and keynote speaker at this year's Patient-Centered Oncology Care meeting, discusses addressing cost of care, using value calculators, and the Medicare Access and CHIP Reauthorization Act.

November 20th 2015

What We're Reading: CMS Wants to Penalize Doctors for Prostate Tests

What we're reading, November 20, 2015: CMS wants to penalize doctors for ordering routine prostate-cancer screening tests; lawmakers, patients, and advocates call for head of Drug Enforcement Agency to be fired; and specialty drug costs exceed household incomes.

November 20th 2015

FDA Seems Poised to Regulate LDTs in Oncology, but Is That a Good Thing?

Mary K. Caffrey

A panel that discussed the prospect of FDA regulation of diagnostic tests in oncology helped open Patient-Centered Oncology Care November 19, 2015, in Baltimore, Maryland.

November 20th 2015

ASCO President Reviews Post-SGR Challenges for Oncologists

Surabhi Dangi-Garimella, PhD

At the Patient-Centered Oncology Care 2015 meeting, held November 19-20, 2015, in Baltimore, Maryland, keynote speaker Julie M. Vose, MD, MBA, FASCO, president of the American Society of Clinical Oncology provided perspectives on the challenges faced by oncologists as the healthcare system transitions to define and incorporate value in the care delivered.

November 19th 2015

Addressing the Elephants in the Room: Healing Through Discussion

Samantha Eisenstein Watson, MBA

Collaboration between organizations serving the young adult cancer population benefits all involved

November 19th 2015

Absence of Prescription Coverage Could Prove Catastrophic in Cancer, Study Shows

Surabhi Dangi-Garimella, PhD

Eligibility for prescription coverage and family income significantly influenced women's decisions to continue hormonal therapy and prevent recurrence of breast cancer, the authors found.

November 18th 2015

ASCO Responds to CMS on Reimbursement Changes Under MACRA

Surabhi Dangi-Garimella, PhD

The American Society of Clinical Oncology has made public its detailed guidance to CMS, supporting implementation of physician-focused and other alternative payment models under MACRA.

Joy Larsen Haidle on How the Genetic Testing Landscape Has Changed

November 18th 2015

Joy Larsen Haidle on How the Genetic Testing Landscape Has Changed

After the Supreme Court struck down gene patents, not only is more genetic testing is being offered, but the technology of the test has expanded to the benefit of patients, said Joy Larsen Haidle, MS, CGC, president of the National Society of Genetic Counselors.

November 18th 2015

Sandoz Biosimilar to Amgen's Neulasta Filed for Regulatory Approval

Surabhi Dangi-Garimella, PhD

This is the company's third biosimilar Biologics License Application in the United States.

November 17th 2015

Tagrisso Approved, but Can Patients With EGFR-Mutant NSCLC Afford It?

Surabhi Dangi-Garimella, PhD

The drug is estimated to cost close to $13,000 per month.

November 17th 2015

FDA Regulation of LDTs: A Report Justifies the Need for It

Surabhi Dangi-Garimella, PhD

It is time to regulate laboratory-developed tests that cost Medicare $9.7 billion in the year 2012 alone.

November 16th 2015

Daratumumab Approval Yields the First Monoclonal Antibody, and Another Option, in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

The drug was approved based on results of 2 open-label studies that showed reduction in tumor burden of patients who had previously received multiple lines of therapy.

November 16th 2015

Should We Trust Screening Age Recommendations in Cancer?

Surabhi Dangi-Garimella, PhD

When to screen and how to screen remain controversial issues in prostate cancer.

This Week in Managed Care: November 14, 2015

November 14th 2015

This Week in Managed Care: November 14, 2015

This week in managed care the top stories include pivotal results from the SPRINT study on blood pressure, an analysis on how states successfully enrolled consumers in the insurance marketplace, and experts discuss value-based care.

November 13th 2015

Creating a Supportive Environment Through the Use of Palliative Care

Laura Joszt, MA

Panelist discuss early referral to palliative care, enduring misconceptions, culture considerations, and more at the Fall Managed Care Forum 2015.

...

117 118 119 120 121 122 123 124 125

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions